

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 20750-0050US1	Application No. 10/593,847
		Applicant John Robert Fritch, et al.	
		Filing Date August 2, 2007	Group Art Unit 1626

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Exam. Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,885,785	03/23/1999	Kao et al.			
	2	6,150,393	11/21/2000	Behan et al.			
	3	6,297,261	10/02/2001	Christophersen et al.			
	4	6,358,698	03/19/2002	Weiner et al.			
	5	6,383,762	05/07/2002	Kao et al.			
	6	6,420,541	07/16/2002	Behan et al.			
	7	2002/0098548	07/25/2002	Kao et al.			
	8	6,531,291	03/11/2003	Kabbash et al.			
	9	6,696,475	02/24/2004	Dahl et al.			
	10	6,846,919	01/25/2005	Behan et al.			
	11	2005/0054691	03/10/2005	Potter et al.			
	12	2005/0080124	04/14/2005	Teegarden et al.			
	13	2005/0267097	12/01/2005	Pinto et al.			
	14	2006/0014705	01/19/2006	Howitz et al.			
	15	2006/0063754	03/23/2006	Edgar et al.			
	16	2006/0205792	09/14/2006	Wong et al.			
	17	2006/0229335	10/12/2006	Teegarden et al.			
	18	2007/0037827	02/15/2007	Nunes et al.			
	19	2007/0072857	03/29/2007	Teegarden et al.			
	20	2007/0207994	09/06/2007	Teegarden et al.			
	21	2007/0244086	10/18/2007	Teegarden et al.			
	22	2007/0293685	12/20/2007	Fritch et al.			
	23	2008/0015223	01/17/2008	Strah-Pleyne et al.			
	24	7,368,539	05/06/2008	Behan et al.			
	25	2008/0200530	08/21/2008	Unett et al.			
	26	2009/0053306	02/26/2009	Agarwal et al.			
	27	2009/0076254	03/19/2009	Behan et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 20750-0050US1	Application No. 10/593,847
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant John Robert Fritch, et al.	
		Filing Date August 2, 2007	Group Art Unit 1626

(37 CFR §1.98(b))

U.S. Patent Documents

Exam. Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	28	2009/0186895	07/23/2009	Tecgarden et al.			
	29	2009/0197935	08/06/2009	Tecgarden et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Exam. Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	30	WO 99/032927	07/01/1999	WIPO				
	31	1147379	12/29/1967	Great Britain				
	32	FR 2 722 369	01/19/1996	France			WO9602138 (abstract only)	
	33	2,135,253	05/08/1996	Canada				
	34	WO 96/023783	08/08/1996	WIPO				
	35	WO 01/029008	04/26/2001	WIPO				
	36	WO 02/051833	07/04/2002	WIPO				
	37	WO 02/076464	10/03/2002	WIPO				
	38	WO 03/062206	01/08/2004	WIPO				
	39	WO 04/045118	05/27/2004	WIPO				
	40	WO 04/058722	07/15/2004	WIPO				
	41	WO 04/028450	10/07/2004	WIPO				
	42	WO05012254	02/10/2005	WIPO				
	43	1 558 582	08/03/2005	Europe				
	44	WO 05/077345	08/25/2005	WIPO				
	45	WO 05/103011	11/03/2005	WIPO				
	46	WO 06/049734	05/11/2006	WIPO				
	47	WO 06/055734	05/26/2006	WIPO				
	48	WO 06/059149	06/08/2006	WIPO				
	49	WO 06/070394	07/06/2006	WIPO				
	50	WO 06/078610	07/27/2006	WIPO				
	51	WO 06/079637	08/03/2006	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 20750-0050US1	Application No. 10/593,847
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant John Robert Fritch, et al.	
		Filing Date August 2, 2007	Group Art Unit 1626

(37 CFR §1.98(b))

Foreign Patent Documents or Published Foreign Patent Applications

Exam. Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub- class	Translation	
							Yes	No
	52	WO 06/086705	08/17/2006	WIPO				
	53	WO 06/095205	09/14/2006	WIPO				
	54	WO 06/097766	09/21/2006	WIPO				
	55	WO 06/100519	09/28/2006	WIPO				
	56	WO 06/112464	10/26/2006	WIPO				
	57	WO 06/116614	11/02/2006	WIPO				
	58	WO 07/002559	01/04/2007	WIPO				
	59	WO 07/026959	03/08/2007	WIPO				
	60	WO 07/120600	10/25/2007	WIPO				
	61	WO 07/129111	11/15/2007	WIPO				
	62	WO 07/136680	11/29/2007	WIPO				
	63	WO 07/136703	11/29/2007	WIPO				
	64	WO 07/136875	11/29/2007	WIPO				
	65	WO 08/027483	03/06/2008	WIPO				
	66	WO 08/042388	04/10/2008	WIPO				
	67	WO 08/054748	05/08/2008	WIPO				
	68	WO 09/023253	02/19/2009	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Exam. Initial	Desig. ID	Document
	69	"Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia", <i>PRNewswire-FirstCall via COMTEX News Network</i> , Press Release dated Dec. 9, 2008 (2 pp.)
	70	Barluenga, J. et al., "A New and Specific Method for the Monomethylation of Primary Amines," <i>J. Chem. Soc. Chem. Commun.</i> , 1984, 20, 1334-1335
	71	Batey, R.A. et al., "An Efficient New Protocol for the Formation of Unsymmetrical Tri- and Tetrasubstituted Ureas," <i>Tetra. Lett.</i> , 1998, 39, 6267-6270
	72	Bernatowicz, M. et al., "A Comparison of Acid Labile Linkage Agents for the Synthesis of Peptide C-Terminal Amides," <i>Tetra. Lett.</i> , 1989, 30(35), 4645-4648
	73	Burger, A., "Isosterism and bioisosterism in drug design", <i>Prog. Drug Res.</i> , 37 (1991), pp. 287-371.
	74	Gutsche, C.D. et al., "2-Phenylcycloheptanone," <i>Org. Syn. Coll.</i> , 1963, vol. 4, 780-783

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 20750-0050US1	Application No. 10/593,847
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant John Robert Fritch, et al.	
		Filing Date August 2, 2007	Group Art Unit 1626

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Exam. Initial	Desig. ID	Document
	75	König, W. et al., "A New Method for Synthesis of Peptides: Activation of the Carboxyl Group with Dicyclohexylcarbodiimide using 1-Hydroxybenzotriazoles as Additives," <i>Chem. Ber.</i> , 1970, 103, 788-798 (English abstract included)
	76	Marchini, P. et al., "Sodium Borohydride-Carboxylic Acid Systems. Useful Reagents for the Alkylation of Amines," <i>J. Org. Chem.</i> , 1975, 40(23), 3453-3456
	77	Sahgal, A. (ed.), "Practical behavioral neuroscience: problems, pitfalls and suggestions," in <i>Behavioral Neuroscience: A Practical Approach</i> , IRL Press, New York, 1993, vol. 1, 1-8
	78	Sheehan, J.C. et al., "1-Ethyl-3-(3-Dimethylamino)Propylcarbodiimide Hydrochloride and Methiodide," <i>Org. Syn. Coll.</i> , 1973, vol. 5, 555-558
	79	Sorenson et al., "Characterization of the 5-HT ₂ sub.2 Receptor Antagonist MDL 100907 as a Putative Atypical Antipsychotic: Behavioral, Electrophysiological and Neurochemical Studies," <i>J. Pharmacol. Exp. Ther.</i> , 1993, 266(2), 684-691
	80	White, E., "Deamination of Amines. 2-Phenylethyl Benzoate Via the Nitrosoamide Decomposition," <i>Org. Syn. Coll.</i> , 1973, vol. 5, 336-339
	81	International Search Report dated Nov. 8, 2004 for International Application No. PCT/US2004/023880
	82	International Search Report dated Dec. 10, 2004 for International Application No. PCT/US2004/023488
	83	International Search Report dated Feb. 20, 2007 for International Application No. PCT/US2006/002721
	84	Restriction Requirement dated May 12, 2009 for U.S. Application Serial No. 11/833,043
	85	Affolter, H., "CA ²⁺ as Messenger of 5HT ₂ -Receptor Stimulation in Human Blood Platelets," <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> , 1984, Vol. 325(4), 337-42
	86	Blier, P. et al., "Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain," <i>Journal of Psychiatry and Neuroscience</i> , 2000, Vol. 26(1), 37-43
	87	Carter, H.E. et al., "Carboboxy Chloride and Derivatives," <i>Org. Syn. Coll.</i> , 1955, Vol. 3, 167-169
	88	Catalán, J. et al., "New Ultraviolet Stabilizers: 3- and 5-(2'-Hydroxyphenyl)pyrazoles," <i>J. Am. Chem. Soc.</i> , 114, 5039-5048 (1992)
	89	Dosa, P.I. et al., "Synthesis and SAR of solubilized pyrazole derivatives as 5-HT _{2a} inverse-agonists for platelet aggregation," 232th ACS National Meeting, Medi 431
	90	Elliott, J. M. et al., "4-Oxospiro[benzopyran-2,4'-piperidines] as Class III Antiarrhythmic Agents. Pharmacological Studies on 3,4-Dihydro-1'-[2-(benzofurazan-5-yl)-ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-one (L-691,121)," <i>J. Med. Chem.</i> , 35:3973-3976 (1992)
	91	Elphick, G. et al., "The human polyomavirus, JCv, uses serotonin to infect cells," <i>Science</i> , 2004, Vol. 306, 1380-3
	92	Grotewiel et al., "Receptors Exhibit Constitutive Activity that is Blocked by Inverse Agonists," <i>Faseb J.</i> , Abstract 353, 8(7), May 21-25, 1994
	93	Gutsche, C.D. et al., "2-Phenylcycloheptanone," <i>Org. Syn. Coll.</i> , 1963, Vol. 4, 780-783
	94	Jeni, J. and Meyerson, L., "The 5-HT _{1A} Receptor Probe[3H]8-OH-DPAT labels ...," <i>Life Sciences</i> , 1988, Vol. 42, 311-320

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 20750-0050US1	Application No. 10/593,847
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant John Robert Fritch, et al.	
		Filing Date August 2, 2007	Group Art Unit 1626
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Exam. Initial	Desig. ID	Document
	95	Ikeguchi, K. and Kuroda, A., "Mianserin Treatment of Patients with Psychosis Induced by Antiparkinsonian Drugs," <i>Eur. Arch. Psych. Clin. Neurosci.</i> , 1995, 244, 320-324
	96	Julius, D. et al., "The 5HT ₂ Receptor Defines a Family of Structurally Distinct but Functionally Conserved Serotonin Receptors," <i>Proc. Natl. Acad. Sci. USA</i> , 1990, Vol. 87, 928-932
	97	Kanayama, M. et al., "New treatment of lumbar disc herniation using 5-hydroxytryptamine _{2a} receptor inhibitor: a randomized controlled trial," <i>Journal of Neurosurgery: Spine</i> , 2005, Vol. 2, 441-6
	98	Kitagawa, O. et al., "Beckmann Rearrangement of O-4 Pentenyl Oxime through N-Bromosuccinimide-Mediated Activating Process," <i>Chem. Pharm. Bull.</i> , 45(1) 32-35 (1997)
	99	Mizuki, Y. et al., "Effects of Mianserin on Negative Symptoms in Schizophrenia," <i>Int. Clinical Psychopharmacology</i> , 1990, 5: 83-95
	100	Muto, T. et al., "Protective effects of sarpogrelate, a 5HT _{2A} antagonist, against posts ischemic myocardial dysfunction in guinea-pig hearts," <i>Molecular and Cellular Biochemistry</i> , 2005, Vol. 272, 119-32
	101	National Institutes of Health, "Facts about Insomnia," NIH Publication No. 95, 1995, 3801
	102	Newton, R.A. and Elliot, J.M., "Mianserin-Induced Down-Regulation of Human 5-Hydroxytryptamine _{2A} and 5-Hydro ...," <i>Journal of Neurochemistry</i> , 1997, 69: 1031-1038
	103	Nishiyama, T., "Effects of 5HT _{2A} receptor antagonist, sarpogrelate on thermal or inflammatory pain," <i>European Journal of Pharmacology</i> , 2005, Vol. 516, 18-22
	104	Nomura, S. et al., "5HT _{2A} receptor antagonist increases circulating adiponectin in patients with type 2 diabetes," <i>Blood Coagulation and Fibrinolysis</i> , 2005, Vol. 16(6), 423-8
	105	Sawnyok, J. et al., "Antidepressants as analgesics: an overview of central and peripheral mechanisms of action," <i>Journal of Psychiatry and Neurosciences</i> , 2001, Vol. 26(1), 21-9
	106	Schmidt, C., "The Role of 5-HT _{2A} Receptors in Antipsychotic Activity," <i>Life Sciences</i> , 1995, 56(25), 2209-2222
	107	Shibata, R. et al., "Adiponectin protects against myocardial ischemiareperfusion injury through AMPK- and COX-2 dependent mechanisms," <i>Nature Medicine</i> , advanced online Publications: 1-8
	108	Van Zwieten, P.A., "Receptors Involved in the Regulation of Vascular Tone," <i>Arzneimittelforschung</i> , 1985, Vol. 35(12A): 1904-9
	109	Verstraete, M., "Prevention of atherosclerotic complications: controlled trial of ketanserin," <i>British Medical Journal</i> , 1989, Vol. 298, 424-30
	110	Vikenes, K. et al., "Serotonin is associated with coronary artery disease and cardiac events," <i>Circulation</i> , 1999, Vol. 100, 483-9
	111	Vippagunta, S. et al., "Crystalline solids," <i>Advanced Drug Delivery Reviews</i> , 48:3-26 (2001)
	112	Wikstrom, H. et al., "Synthesis and Pharmacological Testing of 1, 2, 3, 4, 10, 14b-Hexahydro-6-methoxy ...," <i>J. Med. Chem.</i> , 2002, Vol. 45, 3280-3285
	113	Copy of International Search Report for International Application No. PCT/US2005/041726 dated May 18, 2006 by Authorized Officer Stefan Härtinger.
	114	Copy of International Search Report for International Application No. PCT/US2006/001516 dated June 7, 2006.
	115	Copy of International Preliminary Report on Patentability for International Application No. PCT/US2005/041726 dated September 21, 2006 by Authorized Officer Stefan Härtinger.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 20750-0050US1	Application No. 10/593,847
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant John Robert Fritch, et al.	
		Filing Date August 2, 2007	Group Art Unit 1626

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Exam. Initial	Desig. ID	Document
	116	Copy of the Written Opinion of the International Searching Authority for International Application No. PCT/US2005/041726
	117	Copy of International Search Report for International Application No. PCT/US2007/011810 dated October 30, 2007 by Authorized Officer Bart De Jong.
	118	Copy of International Preliminary Report on Patentability for International Application No. PCT/US2007/011810 dated July 16, 2008 by Authorized Officer Bart De Jong
	119	Nichols, et al. J. Med Chem, 1991, 34, 276-81. See page 302
	120	Tang, et al., Bioorg. Med. Chem. Lett. 203, 13, 2985-88. See Table 1 and page 2987
	121	Yevich et al. Curr. Med.Chem., 1997, 4(5), 295-312. See page 302.
	122	Chambers, et al., Bioorg., Med. Chem. Lett. 2002, 12 1997-99. See page 1997-98.
	123	Glennon, et al., J. Med. Chem., 1982, 25(10), 1163-68. See page 1166-67 and Table II.
	124	Holte, the Practice of Medicinal Chemistry, 2 nd ed., 2003, Wermuth (editor), Academic Press, pages 387-403. See page 394.
	125	"QuaSAR" Research Monograph 22, 1978, NIDA, Barnett and Willette (eds.) See pages 16-25 pages 159-179, Tables 1-8.
	126	John Mandel, "Statistical Analysis of Experimental Data", Chapter 3, pp. 28-57, Toronto, Ontario, (1964)
	127	John Mandel, "Statistical Analysis of Experimental Data", Chapter 9, pp. 204-207, Toronto, Ontario, (1964)
	128	Westkaemper et al., Curr. Topics Med. Chem., 2002, 2, 575-598.
	129	Office Action for Appl. Ser. No. 11/883,043, mailed on Sept. 8, 2009

Examiner Signature /Samantha Shterengarts/	Date Considered 05/21/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./